Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EBS Stock Forecast 2026-2027
$10.99
Current Price
$586.33M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EBS Price Targets
+36.5%
To High Target of $15.00
+22.8%
To Median Target of $13.50
+9.2%
To Low Target of $12.00
EBS Price Momentum
-15.2%
1 Week Change
-10.7%
1 Month Change
+11.2%
1 Year Change
-11.1%
Year-to-Date Change
-21.8%
From 52W High of $14.06
+173.4%
From 52W Low of $4.02
📊 TOP ANALYST CALLS
Did EBS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Emergent BioSolutions is one of their latest high-conviction picks.
Latest EBS Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, EBS has a bullish consensus with a median price target of $13.50 (ranging from $12.00 to $15.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $10.99, the median forecast implies a 22.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 36.5% upside. Conversely, the most conservative target is provided by Robert Wasserman at Benchmark, suggesting a 9.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EBS Analyst Ratings
2
Buy
0
Hold
0
Sell
EBS Price Target Range
Low
$12.00
Average
$13.50
High
$15.00
Current: $10.99
Latest EBS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EBS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Sep 3, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $15.00 |
| Nov 7, 2024 | Benchmark | Robert Wasserman | Buy | Maintains | $12.00 |
| Sep 13, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Reiterates | $16.00 |
| Aug 22, 2024 | Rodman & Renshaw | Buy | Initiates | $16.00 | |
| Aug 16, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Aug 9, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jul 3, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jul 2, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jun 24, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jun 21, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jun 20, 2024 | Benchmark | Robert Wasserman | Buy | Maintains | $8.00 |
| Apr 11, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $5.00 |
| Mar 7, 2024 | Benchmark | Robert Wasserman | Buy | Upgrade | $5.00 |
Emergent BioSolutions Inc. (EBS) Competitors
The following stocks are similar to Emergent BioSolutions based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EBS
Emergent BioSolutions
mkt cap
586.33M
Emergent BioSolutions Inc. (EBS) Financial Data
Emergent BioSolutions Inc. has a market capitalization of $586.33M with a P/E ratio of 8.3x. The company generates $788.90M in trailing twelve-month revenue with a 9.6% profit margin.
Revenue growth is -21.3% quarter-over-quarter, while maintaining an operating margin of +37.8% and return on equity of +13.9%.
Valuation Metrics
Market Cap
$586.33M
Enterprise Value
$1.00B
P/E Ratio
8.3x
PEG Ratio
-0.1x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-21.3%
Gross Margin
+61.3%
Operating Margin
+37.8%
Net Margin
+9.6%
EPS Growth
-55.4%
Financial Health
Cash/Price Ratio
+42.5%
Current Ratio
5.8x
Debt/Equity
115.2x
ROE
+13.9%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Emergent BioSolutions Inc. (EBS) Business Model
About Emergent BioSolutions Inc.
What They Do
Develops and distributes medical products for health threats.
Business Model
Emergent BioSolutions generates revenue through the development, manufacturing, and distribution of medical products, focusing on vaccines, antibody therapeutics, and biodefense solutions. The company collaborates with government and commercial partners to address public health threats, which secures contracts that provide a consistent income stream.
Additional Information
Headquartered in Gaithersburg, Maryland, Emergent BioSolutions is instrumental in national security programs, particularly in the production of critical vaccines for anthrax and smallpox. The company's commitment to emergency preparedness and health security positions it as a crucial player in the global health landscape.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
900
CEO
Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
Country
United States
IPO Year
2006
Website
www.emergentbiosolutions.comEmergent BioSolutions Inc. (EBS) Latest News & Analysis
Latest News
Quick Summary
Emergent BioSolutions Inc. (EBS) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting company developments and strategic initiatives.
Why It Matters
Emergent BioSolutions' presentation may signal strategic developments or financial performance insights, impacting stock valuation and investor sentiment in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Letitia James accused Robert Kramer of insider trading by selling Emergent shares prior to disclosing contamination issues in its Covid-19 vaccine production.
Why It Matters
The accusation of insider trading by Robert Kramer can lead to regulatory scrutiny, impacting Emergent's stock price and investor confidence in the company's management and governance.
Source: WSJ
Market Sentiment:
Negative
Quick Summary
Emergent BioSolutions (NYSE: EBS) has made a voluntary $100 million prepayment on its term loan facility using cash on hand, completed in late December 2025.
Why It Matters
Emergent BioSolutions' $100 million prepayment reduces debt, potentially improving financial stability and creditworthiness, which can positively impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Emergent BioSolutions (NYSE: EBS) has partnered with PANTHER to financially support the Africa CDC-led 'MpOx Study in Africa' (MOSA).
Why It Matters
Emergent BioSolutions' collaboration with PANTHER and financial backing for the Africa CDC's MpOx Study could enhance its market position and growth potential, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Emergent BioSolutions (NYSE: EBS) received a delivery order worth up to $21.5 million from the U.S. Department of War for BioThrax® vaccine in 2026.
Why It Matters
The $21.5 million order from the U.S. Department of War enhances Emergent BioSolutions' revenue prospects and signals government confidence in its products, potentially boosting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
11 days ago
Quick Summary
Emergent BioSolutions CEO Joe Papa will present at the 44th Annual J.P. Morgan Healthcare Conference, as announced on January 7, 2026.
Why It Matters
Joe Papa's presentation at a major investor conference may influence market perception and stock performance of Emergent BioSolutions, signaling strategy and future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EBS Stock
What is Emergent BioSolutions Inc.'s (EBS) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Emergent BioSolutions Inc. (EBS) has a median price target of $13.50. The highest price target is $15.00 and the lowest is $12.00.
Is EBS stock a good investment in 2026?
According to current analyst ratings, EBS has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EBS stock?
Wall Street analysts predict EBS stock could reach $13.50 in the next 12 months. This represents a 22.8% increase from the current price of $10.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Emergent BioSolutions Inc.'s business model?
Emergent BioSolutions generates revenue through the development, manufacturing, and distribution of medical products, focusing on vaccines, antibody therapeutics, and biodefense solutions. The company collaborates with government and commercial partners to address public health threats, which secures contracts that provide a consistent income stream.
What is the highest forecasted price for EBS Emergent BioSolutions Inc.?
The highest price target for EBS is $15.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 36.5% increase from the current price of $10.99.
What is the lowest forecasted price for EBS Emergent BioSolutions Inc.?
The lowest price target for EBS is $12.00 from Robert Wasserman at Benchmark, which represents a 9.2% increase from the current price of $10.99.
What is the overall EBS consensus from analysts for Emergent BioSolutions Inc.?
The overall analyst consensus for EBS is bullish. Out of 11 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are EBS stock price projections?
Stock price projections, including those for Emergent BioSolutions Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 1:40 PM UTC